leisure time -WSS

leisure time

author：knowledge 2025-09-30 23:20:09 - browse：9

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Surge of respiratory disease in China has likely explanation

WSS

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Medicare Advantage enrollment grows 7.1% to 33.4 million people

A new drug could help frostbite victims avoid its ravages

Obamacare plans could cover weight loss drugs

Surge of respiratory disease in China has likely explanation

NYU radiologists take on the challenge of expensive MRI machines

Wikipedia

leisure time

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Weight loss drug costs may need more research, senator suggests

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Wegovy, Zepbound and weight loss drugs that preserve muscle

Drug repurposing or repositioning? The language matters

Astellas still sees hope in its gene therapy after four deaths

Apple is now the first public company to be valued at $3 trillion

Does good food count as health care? Study aims to find out

DIEP, the 'gold standard' of breast reconstruction, is under threat

Abridge raises $150m as clinical notes automation market heats up

focus

Why medical students are struggling with mental health

Elevance, SCAN deals highlight health insurer acquisition scrutiny

David Sabatini, ex

In 'major milestone,' FDA approves first cell therapy for solid tumors

MD Anderson's Padmanee Sharma responds to research credit suit

Morphosys mixed study results for blood cancer drug

Wikipedia

leisure time

hotspot

focus